Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Drops By 53.8%

Adlai Nortye Ltd. (NASDAQ:ANL) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 4,300 shares, a decrease of 53.8% from the September 30th total of 9,300 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a report on Friday, October 18th.

Adlai Nortye Stock Down 0.7 %

Adlai Nortye stock opened at $2.08 on Friday. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48. The stock’s 50 day moving average is $2.28 and its 200-day moving average is $5.44.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.